Ligand id: 7599

Name: etretinate

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: etretinate

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 35.53
Molecular weight 354.22
XLogP 6.77
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Etretinate was used to treat severe psoriasis. The drug was removed from the Canadian and US markets due to the high risk of birth defects associated with its use. Etretinate has been replaced by acitretin, a safer metabolite with a much reduced half-life. The brand name Tigason appears to be in use in Japan.
Mechanism Of Action and Pharmacodynamic Effects
Psoriasis is characterised by aberrant growth of skin cells. Retinoid-induced activation of RAR modulates the expression of genes essential for regulating cell proliferation and differentiation. These drugs may also possess immunomodulatory and anti-inflammatory activities and may inhibit ornithine decarboxylase, an action likely to decrease polyamine synthesis and keratinization. In this way etretinate helps to normalize the growth cycle of skin cells. The precise MMOA has still to be confirmed.